A great deal of evidence has revealed an important link between gut microbiota and the heart. In particular, the gut microbiota plays a key role in the onset of cardiovascular (CV) disease, including heart failure (HF). In HF, splanchnic hypoperfusion causes intestinal ischemia resulting in the translocation of bacteria and their metabolites into the blood circulation. Among these metabolites, the most important is Trimethylamine N-Oxide (TMAO), which is responsible, through various mechanisms, for pathological processes in different organs and tissues. In this review, we summarise the complex interaction between gut microbiota and CV disease, particularly with respect to HF, and the possible strategies for influencing its composition and function. Finally, we highlight the potential role of TMAO as a novel prognostic marker and a new therapeutic target for HF.

Belli, M., Barone, L., Longo, S., Prandi, F.r., Lecis, D., Mollace, R., et al. (2023). Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(15), 1-13 [10.3390/ijms241511971].

Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?

Belli, Martina;Longo, Susanna;Prandi, Francesca Romana;Lecis, Dalgisio;Mollace, Rocco;Muscoli, Saverio;Sergi, Domenico;Federici, Massimo;
2023-07-26

Abstract

A great deal of evidence has revealed an important link between gut microbiota and the heart. In particular, the gut microbiota plays a key role in the onset of cardiovascular (CV) disease, including heart failure (HF). In HF, splanchnic hypoperfusion causes intestinal ischemia resulting in the translocation of bacteria and their metabolites into the blood circulation. Among these metabolites, the most important is Trimethylamine N-Oxide (TMAO), which is responsible, through various mechanisms, for pathological processes in different organs and tissues. In this review, we summarise the complex interaction between gut microbiota and CV disease, particularly with respect to HF, and the possible strategies for influencing its composition and function. Finally, we highlight the potential role of TMAO as a novel prognostic marker and a new therapeutic target for HF.
26-lug-2023
Pubblicato
Rilevanza internazionale
Review
Sì, ma tipo non specificato
Settore MED/06
English
atherosclerosis
cardiovascular diseases
gut microbiota
heart failure
trimethylamine N-Oxide
Belli, M., Barone, L., Longo, S., Prandi, F.r., Lecis, D., Mollace, R., et al. (2023). Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(15), 1-13 [10.3390/ijms241511971].
Belli, M; Barone, L; Longo, S; Prandi, Fr; Lecis, D; Mollace, R; Margonato, D; Muscoli, S; Sergi, D; Federici, M; Barillà, F
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/363026
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact